Democratic lawmakers are pressing the Trump administration on who received special access to Eli Lilly's experimental obesity drug, retatrutide, via the FDA's compassionate use program.[1792065][1805527] The 79-year-old patient, who has refractory obesity, obstructive sleep apnea, and pulmonary hypertension, was granted access to the drug in April.[1792065][1805527] Eli Lilly and the FDA offered retatrutide to the patient through the compassionate use pathway, which gives patients with serious and immediately life-threatening medical issues access to experimental treatments.[1792065][1805527] The move has raised questions about the influence of wealthy donors on drug approvals.[1805527]